AmeriHealth is committed to providing our members with high-quality,
comprehensive, cost-effective prescription drug coverage. The prescription drug
coverage includes a formulary feature, which is a list of drugs approved by the
U.S. Food and Drug Administration (FDA) and selected by the AmeriHealth
Pharmacy and Therapeutics Committee, a group of physicians and pharmacists from
the area. The formulary drugs are selected for their reported medical
effectiveness, safety, and value.
FutureScripts? manages the administration and claims processing
of the AmeriHealth prescription drug programs. FutureScripts works with the
community, mail-order, and specialty pharmacies to provide medications and
customer service to our members and providers. The effectiveness and safety of
drugs and drug-prescribing patterns are monitored by FutureScripts.
Select Drug Program?
The Select Drug Program is an open formulary managed by AmeriHealth. The
formulary is organized by cost-share tiers. The non-preferred tier on the
formulary is generally associated with a higher cost-sharing than the preferred
brand or the generic tiers. Usually, when a brand-name drug has a generic
equivalent, the brand-name drug is covered at the non-preferred level of
cost-sharing while the generic equivalent is covered at the lowest level of
cost-sharing.
- Tier 1 ? Generic: Includes most generic medications. Drugs are
covered at the lowest formulary level of cost-sharing.
- Tier 2 ? Preferred Brand: Includes preferred brand-name
medications. Drugs are covered at a higher formulary level of cost-sharing.
- Tier 3 ? Non-Preferred Drug: Includes non-preferred
medications. Drugs are covered at the highest non-formulary level of
cost-sharing.
Some brand-name drugs without generic equivalents, authorized generic drugs,
and generic drugs are also covered at the non-preferred level of cost-sharing
because there are cost-effective alternatives on the preferred or generic tiers
to treat the same condition.
You can download the latest Select Drug Program Formulary from the AmeriHealth New Jersey and AmeriHealth Pennsylvania websites. To request a
printed copy, call 1-888-YOUR-AH1 for AmeriHealth New Jersey or
1-800-275-2583 for AmeriHealth Pennsylvania.
Value Formulary (for AmeriHealth Pennsylvania
only)
The Value Formulary is a restricted formulary managed by AmeriHealth. The
organization of the cost-share tiers is similar to that of the Select Drug
Program. Drugs not included on the Value Formulary are considered
non-formulary. Non-formulary drugs have covered equivalents and/or alternatives
used to treat the same condition. New drugs are not included on the Value
Formulary until reviewed by the Pharmacy and Therapeutics Committee (P&T).
Formulary placement is determined upon review by the P&T Committee.
Non-formulary exceptions for Value
Formulary members
Providers may request consideration of formulary coverage of a non-formulary
drug when there has been a trial of, or contraindication to, at least three
formulary alternatives when available. The provider should complete a
non-formulary exception request form to provide details to
support use of the non-formulary drug and fax the request to 1-888-671-5285.
If the non-formulary exception request is approved, the drug will be
covered at the highest applicable level of cost-sharing. Please note that
safety edits, such as quantity limits, will still apply. If the request is
denied, the member and provider will receive a denial letter which includes
appeal rights and instructions.
Coverage for drugs is based on the member?s prescription drug benefits. You
can download the latest Value Formulary for AmeriHealth Pennsylvania. To
request a printed copy, call 1-800-275-2583.
Mail-order services
FutureScripts provides mail-order services as an option for AmeriHealth
members to receive their medications. Most of the time, medication requests are
processed upon receipt of a prescription from a provider. However, there may be
times when the provider will be contacted by FutureScripts for medication
coverage, such as when the requested drug requires prior authorization and/or
safety edits apply.
To determine if the drug you prescribed requires prior authorization, please
refer to the Formulary Lookup tool on amerihealth.com. To access the tool for AmeriHealth Pennsylvania, go to Drug Formularies, select
the member?s formulary and then select Find a Formulary Drug. For Value
Formulary members, the provider will also need to select a tier level before
accessing the Lookup tool. To access the tool for AmeriHealth New Jersey go to Drug Programs, then select
Search the formulary. For information on how to request prior authorization for
a drug please review the ?Prescribing safety? section in this article.
Generic equivalent drugs
According to the FDA, generic drugs are equivalent to their brand-name
originator in active ingredients, dosage, safety, strength, and performance and
are held to the same strict standards as their brand-name counterparts. The
only noticeable difference between a generic drug form and its brand-name
counterpart may be the shape and/or color of the drug. Generic drugs are
generally as effective as their brand-name counterparts. However, they may cost
up to 70 percent less, which helps to reduce health care costs for members. The
generic drug option is generally the lowest cost for the member.
FutureScripts does not determine when a generic drug will be provided at the
pharmacy. In accordance with state laws, generic drugs may be provided by the
pharmacist at the point of sale, if available, unless the prescriber indicates
?dispense as written? or ?brand medically necessary? on the prescription. If a
brand-name drug is prescribed in place of a generic drug, prior authorization
may be needed before the drug is dispensed and the members will be responsible
for the higher cost-sharing associated with a brand-name drug.
Therapeutic alternative drugs
Drugs that differ chemically but have the same effect are called
?therapeutic alternatives.? These drugs will generally be in the same
therapeutic class. For example, ibuprofen and naproxen are both non-steroidal
anti-inflammatory drugs that can be therapeutically interchanged in most
cases.
Examples of therapeutic alternatives are:
Brand name
drug | Therapeutic
alternative(s) |
Dulera? | Advair?
Diskus, Symbicort? |
OxyContin? | morphine sulfate ER,
Xtampza? ER |
Lyrica? | gabapentin |
Although they are not the exact chemical equivalents of the brand name
drugs, therapeutic alternatives treat medical conditions in a similar way.
Specialty drugs
Specialty drugs meet certain criteria, including, but not limited to drugs
used to treat rare, complex, or chronic disease, drugs that have complex
storage and/or shipping requirements, and drugs that require comprehensive
patient monitoring and/or education. Specialty drugs covered under the pharmacy
benefit may be managed by FutureScripts. Benefits may vary, and many plans
cover specialty drugs on a specialty tier with higher cost-sharing.
Formulary tier exceptions
Providers may request an exception for a non-preferred drug to be covered at
a preferred level of cost-sharing when there has been a trial of, or
contraindication to, at least three formulary alternatives. This option is
available based on benefit design for both Select Drug Program and Value
Formulary members. The following restrictions apply:
- Drugs on the generic, preferred brand, and the specialty tiers are not
eligible for a change to cost-share.
- Non-formulary drugs on the Value Formulary are not eligible for change
to a lower cost-share. If approved for non-formulary exception, the members
will pay the highest level of cost-sharing for these drugs.
- For cost-sharing purposes, authorized generic drugs are treated as
brand-name drugs and are not eligible for coverage on the generic tier(s).
For example, the authorized generic oxycodone ER is technically a brand-name
drug, not a generic of Oxycontin. Brand-name drugs are not eligible for
coverage on the generic tier. The lowest tier an authorized generic can fall on
is the preferred brand tier.
The provider should complete the formulary exception form, providing details
to support the request and fax it to FutureScripts at 1-888-671-5285.
The request form can be found on the FutureScripts website. If the tier exception request is
approved, the provider will receive a fax notification and the drug will be
processed at the appropriate formulary level of cost-sharing. If the request is
denied, the provider and member will receive a denial letter.
Prescribing safety
As part of formulary management, AmeriHealth implements safe prescribing
procedures that are designed to optimize the member?s prescription drug
benefits by promoting appropriate utilization. These procedures are based on
FDA guidelines, and the approval criteria were developed by the AmeriHeatlh
Pharmacy and Therapeutics Committee. FutureScripts continuously monitors the
effectiveness and safety of drugs and drug prescribing patterns. Several
procedures, such as prior authorization and safety edits, have been established
to support safe prescribing patterns and to promote optimal pharmacotherapy
outcome for the members.
Prior authorization
Prior authorization is required for certain covered drugs to ensure medical
appropriateness and necessity. The approval criteria for these medications may
also include a trial of a different drug, such as a generic equivalent drug or
a therapeutic alternative. Using these approved criteria, clinical pharmacists
evaluate requests for these drugs based on clinical data, information submitted
by the member?s provider, and the member?s available prescription drug therapy
history. The evaluation may include a review of potential drug-drug
interactions or contraindications, appropriate dosing and length of therapy,
and utilization of other drug therapies.
Note: Coverage of certain drugs on the formulary, with or without
prior authorization (e.g., weight loss drugs, fertility drugs), may be limited
based on the member?s prescription drug benefit design.
The prior authorization process may take up to two business days once
complete information from the prescriber has been received. The prescriber will
be notified if an approval has a defined time frame, such as 12 months. Once
the approval time period expires, the provider will need to request
consideration for a new prior authorization.
Providers can access platforms such as CoverMyMeds? and SureScriptsTM that support electronic prior
authorization (ePA) to submit a prior authorization request. Alternatively, the
provider can complete a prior authorization form and fax all supporting medical
information to FutureScripts at 1-888-671-5285. Prior
authorization forms are available on the FutureScripts website.
Prior authorization requirements for
selected drugs
Prior authorization requirements for selected drugs is in place for certain
medications. This expedites the review process at the pharmacy by using
information available in the member?s pharmacy benefit claim history to
determine coverage for the requested medication. For example, Flovent? HFA is a medication that requires previous trial of either of the
preferred medications Asmanex? or Qvar?. With the prior
authorization requirements for selected drugs, a member will be able to receive
coverage immediately for Flovent? HFA if the claim history shows a
previous paid claim for either Asmanex? or Qvar?. A
manual prior authorization request will not be needed. If the claim history
does not contain a previous paid claim of either drug, then a prior
authorization request will be needed in accordance with the standard prior
authorization process.
Safety edits
Safety edits are applied to prescription medications to promote safe and
appropriate use of drugs. They are designed to align with clinical practice
guidelines and FDA approved use(s) outlined in the manufacturer package insert.
There are different types of safety edits; some of which will prompt member
counseling at the point-of-sale, while some will require prior authorization
review. Examples of safety edits are age limits, quantity limits, morphine
milligram equivalent (MME) limits, and concurrent drug utilization review
(cDUR).
Age limits
Age limits are designed to prevent potential harm to members and to promote
appropriate use of the drug. Age groups are identified through the FDA drug
approval process. Age limits are generally noted when safety and efficacy has
not been established. If the member?s prescription falls outside of the FDA
guidelines, it may not be covered until prior authorization is obtained. In
addition, an age limit may be applied when certain drugs are more likely to be
used in certain age groups. For example, drugs used to treat Alzheimer?s
disease may require prior authorization for use in young adults. The provider
may request coverage for drugs outside of the age limit when medically
necessary. If a member?s prescription falls outside the FDA guidelines, it may
not be covered until prior authorization is obtained.
Quantity limits
Quantity limits are designed to allow a sufficient supply of medication
based upon FDA-approved maximum daily doses, standard dosing, and/or length of
therapy of a drug. There are several different types of quantity limits to
promote safe and appropriate utilization. If a member requires more than the
limit, the provider will need to submit a prior authorization request.
Limits | Description | Example |
Quantity over time | This limit is based on dosing guidelines over a rolling time
period. | Sumatriptan (Imitrex?) 50mg,
limit 18 tablets per 30 days |
Maximum daily dose | This limit is based on the maximum daily dose approved by the FDA.
| Guanfacine Extended Release 24-hour, limit 1 tablet per
day |
Refill too soon | This limit is in place to minimize stockpiling of prescription
medications. A prescription drug can be refilled after 75% utilization of its
previous fill. | A 30 days? supply of atorvastatin tablets
filled on 1/1/19 can be refilled again on or after 1/24/19. |
Day supply limit | This limit is based on day supply and not the quantity. However,
quantity limits may apply as well. | Opioids containing cough
and cold products such as hydrocodone/homatropine, limit 5 days? supply per 30
days and 30 ml per 1 day. The max quantity allowed without prior authorization
is 150 ml every 30 days. |
Morphine milligram equivalent (MME)
limits
AmeriHealth applies additional safety measures to opioid products by
limiting the total daily dose. This limit accounts for all the different opioid
products through a measurement called the morphine milligram equivalent (MME)
dose. The MME is a number that is used to determine and compare the potency of
opioid medications and it helps to identify when additional caution is needed.
The daily limit is calculated based on the number of opioid drugs, their
potencies and the duration of therapy. Prior authorization is required for
opioid doses that exceed 90 MME per day.
Concurrent drug utilization review
(cDUR)
Concurrent drug utilization reviews(cDURs) are built into the pharmacy claim
adjudication system to review a member?s prescription history for possible
drug-related problems including drug-drug interactions and drug therapy
duplications. Drugs may reject at the point-of-sale and/or generate a message
to the dispensing pharmacist when there is a safety concern. The dispensing
pharmacist can review the issue with the provider and override the rejection if
appropriate for most edits.
For more information
Visit the Pharmacy section of the AmeriHealth New Jersey or AmeriHealth Pennsylvania websites for additional
information on pharmacy policies and programs.